PT-141 Dosage for Women vs. Men: FDA-Approved vs. Unproven
PT-141 is bremelanotide, the same active ingredient as Vyleesi, an FDA-approved drug. That approval covers exactly one population: premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), dosed at a specific 1.75 mg injection. It does not cover men, postmenopausal women, or sexual performance enhancement, all uses the FDA's own label explicitly excludes. Bremelanotide does have a real, decades-long human trial history in men for erectile dysfunction, it just never reached an approved product.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
Synthetic cyclic heptapeptide, a melanocortin-4 receptor (MC4R) agonist derived from alpha-MSH · also sold or referred to as Bremelanotide, Vyleesi
Photo: Julia Taubitz / UnsplashOne approved dose. One unapproved history.
These aren’t interchangeable numbers for the same population. Read the row before you read the mg.
| What's cited | Range |
|---|---|
| FDA-approved dose (women, HSDD, Vyleesi) | 1.75 mg, subcutaneous, on demand ~45 min before anticipated activity; max 1 dose/24h, no more than 8 doses/month |
| Historical Phase 1/2 subcutaneous dose range tested in men (unapproved) | 0.3-10 mg; erectile response statistically significant above 1 mg in healthy men; 4 mg and 6 mg tested in men with an inadequate response to sildenafil |
| Historical intranasal dose tested in men (route later discontinued) | up to 20 mg; development stopped after dose-related blood pressure increases |
| Active 2024 Phase 2 trial dose (men, PDE5i co-formulation, unapproved) | open-label dose-escalation design; specific dose levels and results not publicly reported as of this writing |
The dose that matters here depends entirely on who's asking, and only one of these has a completed pivotal trial behind it. The FDA-approved figure is a real, label-derived dose studied in two large Phase 3 trials in premenopausal women. The figures for men come from smaller Phase 1 and Phase 2 studies conducted over two decades by bremelanotide's original developer, real human trials, but none large enough or designed to support an approval, and no product for men has ever reached the market.
What “FDA-approved” actually covers here.
Vyleesi’s own label states it “is not indicated for the treatment of HSDD in postmenopausal women, for the treatment of male sexual dysfunction, or to enhance sexual performance.” That’s not marketing caution, it’s the boundary of what two Phase 3 trials actually tested. Bremelanotide sold outside the approved Vyleesi product, whatever the formulation, hasn’t been reviewed by the FDA for that use.
This isn’t theoretical. In an April 2020 warning letter, the FDA cited a compounding pharmacy for producing drug products using “Bremelanotide (PT-141)” among a long list of substances that didn’t qualify for section 503A’s compounding exemptions, meaning those products lacked the legal basis vendors often imply they have.
Real percentages, from the approved population only.
| Signal | Frequency | Context |
|---|---|---|
| Nausea | commonly reported | 40% of VYLEESI-treated women vs. 1.3% on placebo in the pooled Phase 3 trials; 8% discontinued treatment due to nausea (FDA label). |
| Flushing | commonly reported | 20.3% vs. 0.3% on placebo (FDA label). |
| Transient increase in blood pressure, decrease in heart rate | commonly reported | +6 mmHg systolic, +3 mmHg diastolic, -5 bpm heart rate, peaking 2-4 hours post-dose and resolving by about 12 hours (FDA label). This same dose-related blood pressure effect is what ended development of the original intranasal formulation in men. |
| Headache | occasionally reported | 11.3% vs. 1.9% on placebo (FDA label). |
| Injection site reactions | occasionally reported | 13.2% vs. 8.4% on placebo (FDA label). |
| Focal hyperpigmentation (face, gingiva, breasts) | rarely reported | Reported in about 1% of patients using up to 8 doses/month; higher risk with darker skin and daily dosing; resolution was not confirmed in all cases (FDA label). |
| Safety and side-effect profile in men | unknown / not studied | No completed pivotal trial exists for use in men. The historical Phase 1/2 studies were small, safety/PK-focused trials, not designed to establish population-level safety the way the RECONNECT trials did for women. |
FDA-approved (as Vyleesi) for HSDD in premenopausal women only. Not approved for men.
Bremelanotide was approved by the FDA in June 2019 as Vyleesi, based on the RECONNECT program: two replicate Phase 3, randomized, double-blind, placebo-controlled trials (Study 1, NCT02333071, and Study 2) enrolling 1,247 premenopausal women with HSDD. The approved label is specific about what it does not cover: Vyleesi "is not indicated for the treatment of HSDD in postmenopausal women, for the treatment of male sexual dysfunction, or to enhance sexual performance." Unbranded PT-141 sold by research-peptide vendors or compounded into troches, nasal sprays, or other formulations is not the approved Vyleesi product and has not been reviewed by the FDA for safety or efficacy in any of those uses. This is not theoretical: an FDA warning letter to a compounding pharmacy (Tailor Made Compounding LLC, April 1, 2020) specifically named "Bremelanotide (PT-141)" among bulk substances the firm compounded without qualifying for section 503A's exemptions, alongside a long list of other unapproved research peptides. Bremelanotide itself does not appear on the FDA's 503A Category 1 or Category 2 compounding lists (checked directly against the FDA's current bulk drug substance documents), likely because it's the active ingredient of an already-approved drug rather than an unapproved substance under nomination, but that doesn't extend any approval to how vendors are actually selling and using it.
Every claim above, traced back.
The FDA label, the pivotal trial registry entry, two historical male studies, a sponsor trial announcement, and an FDA enforcement letter. Click through and check them yourself.
PT-141 questions, answered.
The active ingredient is identical: both are bremelanotide. The difference is regulatory. Vyleesi is the FDA-approved product, manufactured and labeled for one specific use (HSDD in premenopausal women) at a specific dose. "PT-141" sold by research-peptide vendors or compounded by pharmacies into other formulations is not that approved product and hasn't been reviewed by the FDA for whatever use it's being sold for.
For women, there's an actual FDA-approved answer: 1.75 mg subcutaneously, on demand, no more than once every 24 hours and no more than 8 doses a month, backed by two Phase 3 trials in premenopausal women with HSDD specifically. For men, there's no approved dose. What exists is older Phase 1/2 research testing 0.3-10 mg subcutaneously and up to 20 mg intranasally (a route later discontinued over blood pressure effects), plus a Phase 2 trial combining bremelanotide with a PDE5 inhibitor that started in 2024 with results not yet public.
No. Bremelanotide's original development track in the early 2000s was actually for male erectile dysfunction, using both intranasal and subcutaneous routes, before the intranasal program was stopped over dose-related blood pressure increases. Development later pivoted toward female HSDD, which is what got approved as Vyleesi in 2019. A new Phase 2 trial combining bremelanotide with a PDE5 inhibitor for men who don't respond to PDE5 inhibitors alone started in 2024, but as of this writing there's no completed pivotal trial or approved product for men.
For the approved use in women, the FDA label gives exact figures from the pivotal trials: nausea in 40% of treated patients (vs. 1.3% on placebo, with 8% discontinuing due to it), flushing in 20.3% (vs. 0.3%), a transient rise in blood pressure and drop in heart rate peaking 2-4 hours after dosing, headache in 11.3%, injection site reactions in 13.2%, and focal hyperpigmentation in about 1% of patients using it up to 8 times a month. None of that data exists at the same scale for off-label use in men, since no trial that size has been run in that population.
Keep researching.
This is a preview of the PT-141 report.
Create your account to check any peptide against the full research base.